The MMP-2 level increased with malignancy grade, and high expression was associated with shorter survival in patients diagnosed with grade II-IV astrocytomas as well as in patients with GBM who lived longer than 8.5 months after initial diagnosis. Here, MMP2 is linked to glioblastoma.